JP7644000B2 - 活性化剤 - Google Patents

活性化剤 Download PDF

Info

Publication number
JP7644000B2
JP7644000B2 JP2021514456A JP2021514456A JP7644000B2 JP 7644000 B2 JP7644000 B2 JP 7644000B2 JP 2021514456 A JP2021514456 A JP 2021514456A JP 2021514456 A JP2021514456 A JP 2021514456A JP 7644000 B2 JP7644000 B2 JP 7644000B2
Authority
JP
Japan
Prior art keywords
lck
cell
peptide
cells
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021514456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523945A5 (https=
JP2021523945A (ja
JPWO2019218015A5 (https=
Inventor
アグレス，マイケル，ヴァレンティン
Original Assignee
インテルク ペプチド セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018901672A external-priority patent/AU2018901672A0/en
Application filed by インテルク ペプチド セラピューティクス リミテッド filed Critical インテルク ペプチド セラピューティクス リミテッド
Publication of JP2021523945A publication Critical patent/JP2021523945A/ja
Publication of JP2021523945A5 publication Critical patent/JP2021523945A5/ja
Publication of JPWO2019218015A5 publication Critical patent/JPWO2019218015A5/ja
Application granted granted Critical
Publication of JP7644000B2 publication Critical patent/JP7644000B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021514456A 2018-05-15 2019-05-15 活性化剤 Active JP7644000B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901672A AU2018901672A0 (en) 2018-05-15 Activating Agents
AU2018901672 2018-05-15
PCT/AU2019/050462 WO2019218015A1 (en) 2018-05-15 2019-05-15 Activating agents

Publications (4)

Publication Number Publication Date
JP2021523945A JP2021523945A (ja) 2021-09-09
JP2021523945A5 JP2021523945A5 (https=) 2022-05-24
JPWO2019218015A5 JPWO2019218015A5 (https=) 2022-05-24
JP7644000B2 true JP7644000B2 (ja) 2025-03-11

Family

ID=68539125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514456A Active JP7644000B2 (ja) 2018-05-15 2019-05-15 活性化剤

Country Status (8)

Country Link
US (2) US12134663B2 (https=)
EP (1) EP3794015A4 (https=)
JP (1) JP7644000B2 (https=)
KR (1) KR20210021311A (https=)
CN (1) CN112368293A (https=)
AU (1) AU2019268411B2 (https=)
CA (1) CA3100072A1 (https=)
WO (1) WO2019218015A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912789B2 (en) 2018-05-15 2024-02-27 Interk Peptide Therapeutics Limited Peptide activating agent
CA3120624A1 (en) * 2018-11-30 2020-06-04 Interk Peptide Therapeutics Limited Polypeptides and methods for improving skin conditions
EP4244234A4 (en) * 2020-11-10 2024-12-25 InterK Peptide Therapeutics Limited POLYPEPTIDES AND METHODS FOR IMPROVING SKIN DISEASES
JP2024532850A (ja) * 2021-08-20 2024-09-10 インテルク ペプチド セラピューティクス リミテッド がん及びがん療法に関連する自己免疫を含む、自己免疫を処置するための組成物及び方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007522094A (ja) 2003-09-22 2007-08-09 アシドフィル エルエルシー 小分子組成物、及びその組成物を使用して薬物効率を高めるための方法
WO2009038026A1 (ja) 2007-09-18 2009-03-26 Kurume University Ｃｔｌ誘導剤組成物
JP2010535508A (ja) 2007-08-07 2010-11-25 パデュー リサーチ ファンデイション キナーゼ阻害薬およびその使用
JP2011520436A (ja) 2008-05-14 2011-07-21 イマティクス バイオテクノロジーズ ゲーエムベーハー サービビン由来の新規で強力なｍｈｃクラスｉｉペプチド
JP2012511583A (ja) 2008-12-10 2012-05-24 パーデュー・リサーチ・ファウンデーション 細胞透過性ペプチドを用いたキナーゼ阻害剤
JP2012518602A (ja) 2009-02-23 2012-08-16 インター−ケイ ピーティーワイ リミテッド 複数の細胞活性化経路の阻害
WO2012174412A2 (en) 2011-06-16 2012-12-20 La Jolla Institute For Allergy And Immunology Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
JP2015510393A (ja) 2012-01-24 2015-04-09 インター・ケー・ピーティーワイ・リミテッド 癌治療用ペプチド剤
US20170327543A1 (en) 2010-09-08 2017-11-16 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226552B (it) * 1988-07-29 1991-01-24 Ellem Ind Farmaceutica Peptidi immunostimolanti.
US20030162956A1 (en) 1997-04-07 2003-08-28 Human Genome Sciences, Inc. Leukocyte regulatory factors 1 and 2
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
ATE541940T1 (de) 2001-10-15 2012-02-15 Engeneic Molecular Delivery Pty Ltd Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo
WO2005009346A2 (en) 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
US20060194319A1 (en) 2004-09-02 2006-08-31 Webb Carol F Promoter substitution for immunoglobulin therapy
WO2006029981A1 (en) 2004-09-13 2006-03-23 Vib Vzw Abin-mediated protection against lung inflammatory disease
DK2229956T3 (da) 2004-09-13 2013-07-29 Genzyme Corp Multimere konstruktioner
US7429481B2 (en) 2004-09-14 2008-09-30 University Of Pittsburgh Targeting viruses using a modified sindbis glycoprotein
WO2013033838A1 (en) 2011-09-09 2013-03-14 Pharmagap Inc. Liposomal formulations of cationic peptides and uses thereof
WO2015053338A1 (ja) * 2013-10-08 2015-04-16 学校法人東京理科大学 カチオン性ペプチドおよびそれを含む医薬組成物
JP6367600B2 (ja) 2014-04-18 2018-08-01 矢崎総業株式会社 コネクタ
CN110997693A (zh) 2017-06-07 2020-04-10 阿德克斯公司 τ聚集抑制剂

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007522094A (ja) 2003-09-22 2007-08-09 アシドフィル エルエルシー 小分子組成物、及びその組成物を使用して薬物効率を高めるための方法
JP2010535508A (ja) 2007-08-07 2010-11-25 パデュー リサーチ ファンデイション キナーゼ阻害薬およびその使用
WO2009038026A1 (ja) 2007-09-18 2009-03-26 Kurume University Ｃｔｌ誘導剤組成物
JP2011520436A (ja) 2008-05-14 2011-07-21 イマティクス バイオテクノロジーズ ゲーエムベーハー サービビン由来の新規で強力なｍｈｃクラスｉｉペプチド
JP2012511583A (ja) 2008-12-10 2012-05-24 パーデュー・リサーチ・ファウンデーション 細胞透過性ペプチドを用いたキナーゼ阻害剤
JP2012518602A (ja) 2009-02-23 2012-08-16 インター−ケイ ピーティーワイ リミテッド 複数の細胞活性化経路の阻害
US20170327543A1 (en) 2010-09-08 2017-11-16 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines
WO2012174412A2 (en) 2011-06-16 2012-12-20 La Jolla Institute For Allergy And Immunology Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
JP2015510393A (ja) 2012-01-24 2015-04-09 インター・ケー・ピーティーワイ・リミテッド 癌治療用ペプチド剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
British Journal of Dermatology，2009年，Vol.162, No.1，p.29-41

Also Published As

Publication number Publication date
EP3794015A4 (en) 2022-03-30
EP3794015A1 (en) 2021-03-24
WO2019218015A1 (en) 2019-11-21
US20260103488A1 (en) 2026-04-16
US20210380639A1 (en) 2021-12-09
US12134663B2 (en) 2024-11-05
AU2019268411A1 (en) 2020-12-03
JP2021523945A (ja) 2021-09-09
KR20210021311A (ko) 2021-02-25
CA3100072A1 (en) 2019-11-21
CN112368293A (zh) 2021-02-12
AU2019268411B2 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
US20260103488A1 (en) Activating agents
CN112972492B (zh) Nk细胞中对细胞因子诱导的sh2蛋白的抑制
EP3184117B1 (en) Compositions and their use in the treatment of cancer
US20250019397A1 (en) Peptide Activating Agent
US20200399392A1 (en) Inhibitors of pla2-g1b cofactors for treating cancer
WO2011024482A1 (ja) 抗原特異的ｔ細胞誘導能測定法
US11702632B2 (en) Ex vivo method of generating super regulatory T cells for the prevention of autoimmune disease
KR20210117217A (ko) 제대혈 혈장 유래의 엑소좀 또는 이의 모방체 및 이의 면역억제 용도
CN108834402A (zh) 产生肿瘤浸润t细胞群的方法
FR3110838A1 (fr) Complexe immunomodulateur et ses applications pour la thérapie
JP2022191303A (ja) Ｆｏｘｐ３結合ペプチド及びその使用
CA3184316C (fr) Complexe immunomodulateur et ses applications pour la therapie
남기리 The roles of T cell-intrinsic CD99 and myeloid cell-expressed IDO1 in T cell response
Mohan The role of LKB1 spliceoforms in iTreg-Th17 plasticity and their interactions with PKCθ and SIRT1 downstream of IL-6 signaling
Kujawa Development of small molecule immunomodulators of the human immune system for cancer therapy
WO2025247951A1 (en) Fyn kinase inhibitors, combinations and uses thereof
Sarraf et al. Wnt5A supports antigen cross-presentation and CD8 T cell activation
Tagawa et al. Differential Effects of Aire Gene Deficiency on the Development of Autoimmune Encephalomyelitis Induced by Two Representative Myelin Peptides
Bécart Sonia Feau, Stephen P. Schoenberger, Amnon Altman and

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250227

R150 Certificate of patent or registration of utility model

Ref document number: 7644000

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150